ArticleJournal of neuro-oncology2026
Reasons driving choice and clinical course of patients with CNS WHO grade 3 IDH mutant glioma receiving vorasidenib after surgery: a pilot experience.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAccording to most of international guidelines, patients with newly diagnosed IDH mutant (IDHm) gliomas should receive maximal safe resection followed by a wait-and-see strategy, the IDH mutation inhibitor vorasidenib or sequential radio-chemotherapy (RT/CT) based on risk factors of progression such as extent of resection, neurological symptoms and WHO grading. However, it is not clear how the historical risk factors of progression should drive decision-making in molecular era. It is still unknown whether IDH inhibition may be appropriate in patients with WHO grade 3 IDHm gliomas, particularly when expected tumour growth rate is slow and delaying RT/CT is not a concern.
methodsWe retrospectively reviewed the clinical data of patients with WHO G3 IDHm gliomas in 4 reference neuro-oncological centres. The patients were treated only with surgery and were considered eligible for vorasidenib at the dose of 40 mg daily within the drug early access programme.
resultsA total of 10 patients were included (6 astrocytoma, 4 oligodendroglioma). Good Karnofsky performance status (90-100%), no neurological focal signs/symptoms and no need of corticosteroid guided the choice of vorasidenib in all cases (10/10). The 6 month and 12 month-PFS were 90% and 77.1%, respectively. In one case (10%) there was a grade 3 elevation in liver function tests, necessitating dose reduction.
conclusionsPreserved clinical conditions guided the choice of IDH mutation inhibitor in all cases, with preliminary efficacy and safety data consistent with those of the INDIGO trial. Future studies should address the most appropriate role of vorasidenib in this setting.
Indexed as
Identifiers
41604034What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.